TherapeuticsMD, Inc. — Director's Dealing 2023

Dec 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2023-12-05

Reporting Person: Walker Marlan D (Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-05	Common Stock	M	70000	$0.00	Acquired	81615	Direct
2023-12-06	Common Stock	S	14500	$2.3101	Disposed	67115	Direct
2023-12-07	Common Stock	S	4550	$2.239	Disposed	62565	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-05	Restricted Stock Units	$0.00	M	70000	Disposed		Common Stock (70000)	Direct

Footnotes

F1: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $2.22 through $2.48, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $2.15 through $2.31, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth.

F4: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on June 30, 2023.